Fusion Antibodies plc
FAB.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.02 | -0.03 | 0.22 |
| FCF Yield | -23.30% | -82.80% | -18.66% | -3.80% |
| EV / EBITDA | -3.42 | -0.48 | -3.99 | -23.71 |
| Quality | ||||
| ROIC | -249.06% | -118.60% | -205.30% | -31.23% |
| Gross Margin | 21.88% | -23.33% | 6.96% | 35.78% |
| Cash Conversion Ratio | 0.80 | 0.79 | 0.68 | 0.28 |
| Growth | ||||
| Revenue 3-Year CAGR | -12.18% | -38.14% | -11.36% | 7.20% |
| Free Cash Flow Growth | 22.42% | 5.24% | -216.24% | 61.02% |
| Safety | ||||
| Net Debt / EBITDA | 0.21 | 0.56 | 0.05 | 3.46 |
| Interest Coverage | -593.00 | -457.60 | -708.25 | -148.00 |
| Efficiency | ||||
| Inventory Turnover | 5.71 | 3.05 | 5.01 | 5.27 |
| Cash Conversion Cycle | 37.18 | 225.08 | 127.88 | 139.44 |